Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880225 | 0.82 | CES2 (0.64) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL182755 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL19075433 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL6495770 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL2743436 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL3655196 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL8578258 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL28800304 | 0.80 | CES2 (0.61) | CES2CES1SRD5A2PTGS1TRPV1 | |
| SCHEMBL29208531 | 0.79 | SRD5A2 (0.83) | CES2CES1SRD5A2GSK3BPTPN1 | |
| SCHEMBL6991977 | 0.78 | CES2 (0.59) | CES2CES1SRD5A2PTGS1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160692-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2022-05-26 | — | — | US | disclosed |
| CN-103012378-A | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARM INC | 2013-04-03 | — | — | CN | disclosed |
| CN-102977029-A | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARM INC | 2013-03-20 | — | — | CN | disclosed |
| CN-101084195-B | As 5-HT2A3-phenyl-pyrazole derivatives useful as serotonin receptor modulators for the treatment of disorders related thereto | ARENA PHARM INC | 2013-01-02 | — | — | CN | disclosed |
| CN-1816550-B | Indolyl derivatives substituted with a thiazole ring and their use as PPAR modulators | HOFFMANN LA ROCHE | 2010-04-28 | — | — | CN | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| CN-1816550-A | Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | CN | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160692-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | SPHK2, SPHK1, S1PR2 | CES2 4564/4885CES1 2288/4885SRD5A2 3038/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CES2 953/4885CES1 2154/4885SRD5A2 3597/4885 |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | CES2 1620/4885CES1 2219/4885SRD5A2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.